Oracle chairman Larry Ellison has announced that AI will soon develop customised mRNA vaccine against cancer for every ...

Evaxion introduces EVX-04, a novel vaccine candidate targeting multiple non-conventional ERV tumor antigens, developed withour AI-Immunology™ ...

Evaxion Biotech ( ($EVAX) ) has shared an update. On November 3, 2025, Evaxion A/S announced the expansion of its R&D pipeline with the ...

New biomarker and immune data from the ongoing phase 2 trial with EVX-01 will be presented at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting The data will be the latest of many ...

In a new study, University of Arizona researchers created a model for cutaneous squamous cell carcinoma, a type of skin ...

COPENHAGEN, Denmark, October 13, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will present a wide range ...

The human papillomavirus (HPV) vaccine is one of the few vaccines proven to prevent cancer-so why have only 61% of teens 13-17 and far lower percentages of younger children received the potentially ...

The integration of single-cell RNA sequencing (scRNA-seq) with AI has become a cornerstone for deciphering tumor heterogeneity. For instance, in pancreatic ductal adenocarcinoma (PDAC), spatial ...

The U.S. government has canceled $500 million in funding for mRNA vaccine research, raising concerns about future vaccine development. Kristen Dahlgren, CEO of the Cancer Vaccine Coalition, remains ...

Scientists have developed a cancer vaccine that stopped three different types of aggressive tumors from growing in mice.

UMD professors Cheryl Knott, Xiaoli Nan (PI) and Min Qi Wang. The human papillomavirus (HPV) vaccine is one of the few vaccines proven to prevent cancer—so why have only 61% of teens 13-17 and far ...

Researchers found that lung and skin cancer patients who got COVID-19 vaccines reported significantly increased survival ...